Prot #GSK 201585: A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI- NNRTI-, or PI

Project: Research project

Project Details

StatusFinished
Effective start/end date2/7/172/7/20

Funding

  • PPD Investigator Services, LLC (Prot #GSK 201585)
  • GlaxoSmithKline LLC (Prot #GSK 201585)